Saturday 17 October 2026
Export CTOR’s income statement to Excel — free account
Citius Oncology, Inc.
CTOR Healthcare Drug Manufacturers Specialty & Generic
In the quarter to June 2026, EPS was flat, free cash flow was flat and total debt rose 79.3%, each against the same quarter a year earlier.
0.75
0.00
0.00%
Follow CTOR
Citius Oncology, Inc. (CTOR) P/E ratio
Citius Oncology, Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (October 2026) to 305× (August 2024) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Quarterly newest first
| Period | P/E ratio | Change |
|---|---|---|
| Jun 2026 | 0.0× | — |
| Mar 2026 | 0.0× | — |
| Dec 2025 | 0.0× | — |
Against its own ten years
Low 0.0×
High 305×
Ten-year median
0.0×
Current reading's percentile
67
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| CPIX Cumberland Pharmaceuticals Inc. compare | n/m |
| SCYX SCYNEXIS, Inc. compare | n/m |
| CTOR Citius Oncology, Inc. | n/m |
| CLVR Clever Leaves Holdings Inc. compare | n/m |
| TLPH Talphera, Inc. compare | n/m |
| PROCF Sofgen Pharma S.A compare | 0.1× |
| INCR InterCure Ltd. compare | 8.8× |
| BGM BGM Group Ltd. compare | 144× |
| ZYBT Zhengye Biotechnology Holding Limited compare | — |
| Drug Manufacturers Specialty & Generic industry median | 19.2× |
| Healthcare sector median | 23.0× |
| Market median | 18.1× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)